Ketek, or telithromycin, is an antibiotic approved by the FDA in 2004 for treating bacterial infections, particularly in the lungs, sinuses, and throat; it is not effective against viral infections. Serious side effects, including liver damage and hepatitis, have been linked to Ketek, leading to legal claims against its manufacturer, Sanofi-Aventis. Allegations of FDA misconduct during Ketek's approval process raise concerns about data integrity related to its clinical studies.